Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona histologicznie rozlana chłoniakowa choroba z dużych komórek B lub wysokozłośliwy chłoniak z komórek B
- •Brak wcześniejszego leczenia tego chłoniaka
- •Nienadający się do standardowego silnego chemioterapii ze względu na: wiek 80+ lat, słabe ogólne samopoczucie lub starczość
- •Słaba funkcja serca (EF 30-50%) lub wcześniejsze silne chemioterapie kardiologicznie toksyczne
- •Zaawansowana choroba (stadium II z guzem >7cm, III lub IV)
- •Dobre funkcje nerek, wątroby i szpiku kostnego
- •Możliwe do zmierzenia ogniska choroby widoczne w badaniach obrazowych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Dai Chihara, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.